Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration approved CAPLYTA (lumateperone) as an adjunctive therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE